Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

University of Kansas Medical Center36 enrolled

Overview

The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.

Polycystic Kidney Disease (PKD) is a genetic disease that affects about 1 in 500 people worldwide. It can lead to kidney failure which can lead to death. PKD causes the development of kidney cysts (fluid-filled balloons), which cause worsening kidney function. It is common for people with PKD to also have blood in the urine, kidney pain, high blood pressure, kidney stones, kidney infections, and cysts in the brain or other parts of the body. There is currently no treatment known to stop cyst growth or a cure for the disease. Participants in this study will be randomly assigned to one of two groups: niacinamide or placebo. Participants have an equal chance of being assigned to either of the groups. For people that qualify and decide to participate in this study, they will be asked to make five visits to the study clinic and complete two study related phone calls over the course of 12 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Polycystic Kidney Disease

Interventions

NiacinamideDIETARY_SUPPLEMENT

PlaceboOTHER

Placebo pill that matches niacinamide pill is size, shape and color

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD). * Estimated glomerular filtration rate (eGFR) \> 50 ml/min/1.73m2 as determined from the serum creatinine by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation * Provide Informed consent Exclusion Criteria: * History of liver disease or abnormal liver function test * Heavy alcohol intake * Chronic diarrhea or malabsorption syndrome * Thrombocytopenia * Hypophosphatemia * Pregnancy or lactation or plan to become pregnant during the study * Treatment with anti-epileptic drugs * Treatment with tolvaptan, current or within 2 months prior to screening * Participation in another interventional trial currently or within 2 months prior to screening. Exclusions specific to magnetic resonance (MR) imaging acquisition and measurement: * Partial or total nephrectomy or renal cyst reduction (including aspiration) done \<1 year ago * Cardiac pacemaker. * Presence of MR incompatible metallic clips (e.g. clipped cerebral aneurysm) * Body weight \>159 kg (350 lbs) or untreatable claustrophobia.

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Outcomes

Primary Outcomes

Change in acetylated/total p53 ratio measured by ELISA in peripheral blood mononuclear cells (PBMC)

Sirtuin 1 deacetylates p53 protein, and niacinamide inhibits sirtuin 1. So an increase in acetylated/total p53 ratio in PBMC will be used as a marker of biological efficacy.